Imperfect use of contraceptive methods notably increases the likelihood of pregnancy. One
means of improving user adherence with hormonal contraception is to minimize the dosing …

Objective: The objective of this study was to identify the dose for a contraceptive patch that
provides a predetermined level of ovulation suppression and cycle control and that is well …

En] Summary Abstract Ethinylestradiol 20 μg/day plus norelgestromin 150 μg/day have been
formulated into a transdermal patch for hormonal contraception. The predominant …

The transdermal contraceptive system or contraceptive patch (Ortho EVRA, Ortho-McNeil
Pharmaceuticals, Raritan, NJ), approved by the Food and Drug Administration in November …

Introduction: The first contraceptive patch with ethinyl estradiol (EE) and norelgestromin in
the United States demonstrated that there was a tremendous interest in topical methods …

The transdermal contraceptive patch which contains ethinyl estradiol and norelgestromin
has an efficacy similar to current oral contraceptives (OCs). The major advantages include …

OBJECTIVES: To evaluate the efficacy, cycle control, compliance, and safety of a
transdermal contraceptive system that delivers norelgestromin 150 μg and ethinyl estradiol …

Abstract Objective: To document Canadian women's experience with the transdermal
contraceptive patch, a method delivering 150 μg norelgestromin and 20 μg ethinyl estradiol …

This open‐label, randomized, 2‐way crossover study characterized the pharmacokinetics
and pharmacodynamics of a transdermal contraceptive patch and a norgestimate …

Transdermal drug delivery systems have been available in the United States for> 20 years.
Since the introduction of the first transdermal patch (scopolamine) for the treatment of motion …